Tevogen Bio (TVGN) to Post Quarterly Earnings on Thursday

Tevogen Bio (NASDAQ:TVGN) is projected to announce its results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($2.5350) per share for the quarter.

Tevogen Bio (NASDAQ:TVGN) last issued its quarterly earnings results on Friday, May 15th. The company reported ($1.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.64) by $1.03.

Tevogen Bio Trading Down 1.2%

TVGN opened at $6.39 on Tuesday. The stock has a market capitalization of $26.97 million, a PE ratio of -1.39 and a beta of 0.18. Tevogen Bio has a 1-year low of $3.64 and a 1-year high of $55.00. The firm has a 50-day moving average price of $7.17 and a two-hundred day moving average price of $8.57.

Institutional Investors Weigh In On Tevogen Bio

Institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. boosted its stake in Tevogen Bio by 126.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after acquiring an additional 152,572 shares during the last quarter. Deutsche Bank AG raised its position in shares of Tevogen Bio by 304.1% during the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after acquiring an additional 130,738 shares during the last quarter. Finally, Bridgeway Capital Management LLC raised its position in shares of Tevogen Bio by 66.7% during the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after acquiring an additional 33,000 shares during the last quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a research note on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $100.00.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.